Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9596829 | 0.98 | ALDH1A1 (0.33) | ALDH1A1RAB9APSMB5 | |
| SCHEMBL238978 | 0.94 | — | — | |
| SCHEMBL7487899 | 0.77 | CHRM2 (0.32) | — | |
| SCHEMBL7732731 | 0.72 | MEN1 (0.31) | — | |
| SCHEMBL7834163 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL520941 | 0.70 | — | — | |
| SCHEMBL925364 | 0.70 | — | — | |
| SCHEMBL623051 | 0.70 | MAPK1 (0.35) | — | |
| SCHEMBL895316 | 0.70 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL7741439 | 0.70 | CYP1A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-2631237-A2 | Total synthesis of salinosporamide A and analogs thereof | Nereus Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-2013167-B1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8067616-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110105762-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7842814-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2013167-A2 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | Nereus Pharmaceuticals, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007117591-A9 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS INC (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0930302-A2 | Benzosulfone derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998023587-A1 | 5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-06-04 | — | — | WO | disclosed |
| US-5656754-A | REACTING AN ALLENYL-B-LACTAM COMPOUND WITH AN ORGANOTIN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5646283-A | IMMUNOSUPPRESSANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5574055-A | COGNITIVE AND NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0721942-A1 | NOVEL TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0657440-A1 | Oxazolidine-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |
| EP-0623622-A1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1994-11-09 | — | — | EP | disclosed |
| US-5292732-A | Pyrrolopyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0521368-A1 | Bi- and tetracyclic pyrrolopyrazines | F. HOFFMANN-LA ROCHE AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105762-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | ERG28, CYP51A1, LSS | ALDH1A1 2061/4885RAB9A 1782/4885PSMB5 2109/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3667/4885RAB9A 45/4885PSMB5 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.